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Alteration of Topoisomerase II Action Is a
Possible Molecular Mechanism of HL-60
Cell Differentiation
by F. Gieseler,* F. Boege,* and M. Clark*
The inhibition of differentiation and persistence of proliferation in cell transformation is probably not
only caused by the mutation ofsingle genes. An additional mechanism oftranscriptional control, not only
of single genes but of gene programs, is possibly the alteration of the topoisomerases. These enzymes
regulate the conformation of DNA by twisting and unwinding the double strands. As has been shown
previously, only the genes located in relaxed DNAareas are transcribed and, therefore, the topoisomerases
can be described as a gene regulation device. We present the hypothesis that topoisomerase II action is
not only altered in, but also necessary for, HL-60 granulocytic cell differentiation. Thus, alteration of
topoisomerases may well be a molecular mechanism of cellular differentiation.
Introduction
Hematopoiesis is one of the best understood differ-
entiation systems. The knowledge ofthe differentiation
state of the original cell of a leukemic clone or a lym-
phoma allows the exact diagnosis and choice of the
proper therapy. This is the basis for clinical diagnostic
systems such as the FAB-classification (French-Amer-
ican-British) of leukemias and the Kiel classification of
malignant lymphomas. The Kiel classification enables
one to definethe malignant cell as acellthat is disturbed
and blocked in its differentiation. However, a therapy
derived fromthebiology (e.g., differentiation induction)
has not been established. One reason is the lack of
knowledge of the molecular mechanisms of cell differ-
entiation and transformation.
To date only a very small minority of human malig-
nomas could be identified as being caused by chromo-
somal translocations or point mutations in single genes.
For example, less than 30% ofhuman malignomas have
a point mutation in the ras gene family. These facts
suggest the existence of additional mechanisms that
could very likely involve the transcription regulation
not only of single genes but of whole gene programs.
It has been discussed previously that a change in
DNAcytosine methylation is oneregulatory mechanism
in the long-term control of gene transcription. This ob-
viously does not play a role in the granulocytic differ-
entiation ofHL-60 cells, as we have reported in arecent
publication (1).
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Another possible mechanism is a change in the DNA
conformation. There are two typical DNA conforma-
tions: supercoiled and relaxed. The enzymes that reg-
ulate conformational changes of the DNA are the to-
poisomerases. It is a well-known fact that only genes
that are located in relaxed areas ofthe DNA are tran-
scribed (2). Thus, the topoisomerases are unique gene
transcription regulating enzymes.
Two different types oftopoisomerases are described
and can be distinguished by their different assay re-
quirements: thetopoisomerasetype IIdependsonMg2'
and ATP, whereas the topoisomerase type I is ATP
independent (3). BothenzymeshaveaswellDNA-twist-
ing as DNA-unwinding activities. The factors that in-
fluence the directionare notcompletelyunderstood, but
by varying the assay conditions the topoisomerase-ac-
tion can be separated in several different steps (4).
In this paper we present evidence that a change in
topoisomerase II activity is one additional mechanism
in the regulation ofgenes that control hematopoetic cell
differentiation. In the experiments shown, we used the
HL-60 cell system and induced granulocytic differen-
tiation with the help of dimethylsulfoxide (DMSO).
Materials and Methods
Chemicals, Media, and Cell Culture
The chemicals andmediaused are commercially avail-
able: RPMI 1640 medium, fetal calf serum, HEPES
(Bethesda Research Laboratories, Karlsruhe, FRG),
EDTA, DMSO, and mercaptoethanol (Sigma Chemical
Co. Ltd., Deisenhofen, FRG).
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lection, Rockville, MD) as well as differentiation induc-
tion were performed as described previously (1).
Assessment of Topoisomerase II Activity
Nuclei of 3 x 10O cells were isolated as follows (all
steps on ice): wash twice with isotonic buffer (e.g.,
PBS), resolve in 8 mL lysis buffer (0.3 M sucrose, 0.5
mM EGTA, 60 mM KCI, 15 mM NaCl, 0.15 mM sperm-
ine, 0.05 mM spermidine, 15 mM HEPES, pH 7.5, 14
mM 2-mercaptoethanol), add 40 ,uL prewarmed Triton
X-100, gently mix for 15 min on ice, sediment (lOOOg,
5min, 0°C inaswing-outrotor), countnucleiafterstain-
ing with trypan blue, resuspend in 2 mL lysis buffer
(without Triton X-100), sediment through 7 mL 30%
sucrose inlysisbuffer. Recoveryshouldbealmost 100%.
Nuclei can be stored at -70°C for months in 100-,uL
aliquots, 2 x 105 nuclei per microliter storage buffer
[20 mM tris, pH 7.9, 75 mM NaCl, 0.5 mM EDTA, 0.85
mM DTT, 0.125 mM phenylmethylsulfonyl fluoride
(PMSF) stock200mMinisopropanolor10-4Mtrasylol,
50% glycerine].
Topoisomerase II solution was made as described
with slight variations (5): nuclei were collected by cen-
trifugation (200g for 10 min) and resuspended at 3 x
107 mL in 5 mM potassium phosphate, pH 7.5, 100 mM
NaCl, 10 mM 2-mercaptoethanol, 0.5 mM phenyl-
methylsulfonylfluoride. NaCl (5 M) was added to afinal
concentration of 0.35 M, and the nuclei were mixed
gently on a Vortex mixer, incubated on ice for 60 min,
and sedimented (lOOOg for 10 min).
For relaxation experiments a 5-,uL aliquot ofthe su-
pernatant fraction was mixed with 5 ,uL reaction buffer
(100 mM Tris-HCl, pH 7.5, 200 mM KCl, 1 mM EDTA,
0.3 ,ug bovine serum albumin) and 200 ng pBR322 plas-
mid DNA. For topoisomerase II activation, 10 mM
MgCl2 and 10 mM ATP was added fresh. After incu-
bationat37°C for60min, the DNAwaselectrophoresed
in a 1% agarose gel and visualized by staining with
ethidium bromide after electrophoresis.
We used a large-scale plasmid preparation and iso-
lation by the alkaline method described by Maniatis (6)
to isolate PBR322 plasmids from E. coli.
Results
A marked increase of topoisomerase II activity can
be monitored ingranulocytic HL-60 cell differentiation,
as shownin Figure 1. The HL-60 cells had been induced
to differentiate by culturing for 5 days in the presence
of DMSO (1% v/v). Differentiation was confirmed with
the help ofthe followingmarkers: cellgrowth, viability,
and nitro-blue tetrazolium-reduction (NBT test). The
differentiated cells accumulated in the Go phase and
stopped dividing. Viability was always more than 80%.
To distinguish between topoisomerase I and topo-
isomerase II activity, we performed experiments ofthe
kindshowninFigure2. Ithasbeendescribedpreviously
that topoisomerase II is activated and topoisomerase I
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FIGURE 1. Topoisomerase II activity of undifferentiated and gran-
ulocytic differentiated HL-60 cells. Approximately 200 ng plasmid
DNAandnuclearextractfrom 10i cellswereusedperexperiment.
Lanes 1-3, HL-60cells(1:2, 1:4, 1:8);lanes4-6, HL-60cells/DMSO
(1:2, 1:4, 1:8); lane 7, control (pBR322, 200 ng).
1 2 3 4
opencircldar
andidaxe
a
- ople circular
- reaed
FIGURE 2. Differentiation between topoisomerase I and topoiso-
merase II activity and the open circular and relaxed form of
pBR322 plasmid. Approximately250ngplasnid DNAandnuclear
extractfrom 10i cells wereused perexperiment. Lane 1, pBR322,
250 ng; lane 2, pBR322 plus extract; lane 3, pBR322 plus ATP and
Mg; lane 4, pBR322, extract, ATP, Mg, and EtBr.
is blocked by the addition ofATP to the reaction buffer
(7). We found very little relaxation activity without the
addition ofATP, which we contribute either to a slight
topoisomerase I activity ortothe endogenous ATP con-
tent in the nucleic extracts we used (-0.1 mM). From
these experiments we conclude that the relaxation ac-
tivity we found is mainly due to topoisomerase II ac-
tivity and not to topoisomerase I.
By intercalation of ethidium bromide, the open cir-
cular plasmid DNA and the supercoiled plasmid DNA
can be separated. The open circular form results from
single strand nicks that occur on isolation of the plas-
mids from E. coli bacteria. Addition of ethidium bro-
mide to the gel running buffer results in intercalation
into the DNA molecule, which increases the spacing of
successive base pairs and subsequently decreases the
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pitch ofthe helix. The two forms can then be separated
by their different migration speeds in agarose gel elec-
trophoresis as shown in Figure 2.
Discussion
Topoisomerase II inhibitors are strongly cytostatic
substances because topoisomerase action is needed for
cell division as well as for gene transcription. Addition
of these inhibitors in sublethal concentrations to the
medium of HL-60 cells can also induce differentiation
and blockthe induction ofdifferentiation by DMSO. We
have published both observations previously: granulo-
cytic differentiation can be induced by the addition of
mitoxantrone 2 x 1o-8 M (8), and DMSO-induced dif-
ferentiation can be inhibited by the addition of 4'-(9-
acridinylamino)methanesulfon-M-aniside (m-AMSA)
10-8 M (9). These results, which appear contradictory
at first, represent the highly specific.mode of action of
topoisomerase II. In order to control gene transcription
the enzyme hastorecognize specific DNA-bindingsites;
the existence of these sites had been shown several
times. Moreover, topoisomerase II induces cleavage
sites in promoter-active DNA regions, which has been
described previously for the c-myc proto-oncogene (10)
and the c-fos proto-oncogene (11). Both genes obviously
play important roles in proliferation and differentiation
ofhematopoetic cells.
In this paper we have shown that topoisomerase II
activity increases in granulocytic differentiated, HL-60
cells (Fig. 1), in spite of the markedly reduced prolif-
eration capacity ofthe differentiated cells. We attribute
this result to the higher transcriptional rates of the
specific genes that code for the specific abilities Qf the
differentiated cells (e.g., reductase activity, phagocy-
tosis). Combination with the previously published re-
sults described above shows that topoisomerase II ac-
tion is not only altered in but is also necessary for
granulocytic HL-60 cell differentiation.
In the experiments described here, we used assay
conditions that prefer topoisomerase II activity. We
confined ourselves to topoisomerase II activity because
it had been shown that this enzyme is the molecular
target for a number of clinically relevant cytostatics,
such as anthracyclines (e.g., doxorubicin, mitoxan-
trone), podophyllotoxins (e.g., etoposid, tenoposid), and
synthetic substances (e.g., m-AMSA) (12). These sub-
stances act via inhibition of an intermediate DNA-en-
zyme complex, which results in DNA double-strand
breaks with covalently bound proteins (the topoisomer-
ase subunits). The number of these topoisomerase II-
induced DNA double-strand breaks can be correlated
with the cytotoxicity ofthe substances (13).
Thiswayofcytostatic actioncanalsobeusedtodefine
the DNA-binding sequences oftopoisomerase II by us-
ing restriction enzyme fragment length polymorphism
(RFLP analysis) of the DNA areas of interest to de-
termine the sites of the strand breaks. If an altered
topoisomerase II was one ofthe molecular mechanisms
ofHL-60 cell differentiation, one would expect not only
an altered topoisomerase activity but also altered DNA
binding sites in order to relax different DNA regions.
We plan to test this hypothesis in the near future.
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